U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07003074) titled 'A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer' on May 21.
Brief Summary: This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: TQB2102 for Injection
TQB2102 is a next-generation HER2 Antibody-Dru...